Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer

Neoplasia (United States)

Volumn 15, Issue 4, 2013, Pages 399-408

  Yang, Bing ^a   Bhusari, Sachin ^a   Kueck, Jessica ^a   Weeratunga, Pushpa ^a   Wagner, Jennifer ^a   Leverson, Glen ^a   Huang, Wei ^a,b   Jarrard, David F ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; CAVEOLIN 1; FIBROBLAST GROWTH FACTOR 1; GROWTH DIFFERENTIATION FACTOR 5; METABOTROPIC RECEPTOR 8; MICROTUBULE ASSOCIATED PROTEIN 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NEUREXIN; PHOSPHATIDYLINOSITOL KINASE; PROTEIN P53; SEPTIN; SYNAPSIN; WNT2 PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; GENE EXPRESSION; GENE LOCUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84875641446     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13280     Document Type: Article

References (39)

1. Slaughter DP, Southwick HW, and Smejkal W (1953). Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6, 963-968.
2. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, et al. (2006). High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12, 989-995.
3. Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, and Yoshida O (1998). Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 58, 5835-5841.
4. Kamiyama H, Suzuki K, Maeda T, Koizumi K, Miyaki Y, Okada S, Kawamura YJ, Samuelsson JK, Alonso S, Konishi F, et al. (2012). DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene 31, 5029-5037.
5. Aitchison A, Warren A, Neal D, and Rabbitts P (2007). RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 67, 638-644.
6. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, and Woodson KG (2006). Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 98, 255-261.
7. Henrique R, Jeronimo C, Teixeira MR, Hoque MO, Carvalho AL, Pais I, Ribeiro FR, Oliveira J, Lopes C, and Sidransky D (2006). Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 4, 1-8.
8. Miller GJ and Cygan JM (1994). Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 152, 1709-1713.
9. Schulz WA and Hoffmann MJ (2009). Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 19, 172-180.
10. Bird A (2002). DNA methylation patterns and epigenetic memory. Genes Dev 16, 6-21.
11. Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, et al. (2011). Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 30, 1390-1401.
12. Wu YH, Tsai Chang JH, Cheng YW, Wu TC, Chen CY, and Lee H (2007). Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers. Oncogene 26, 4761-4773.
13. Eden A, Gaudet F, Waghmare A, and Jaenisch R (2003). Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300, 455.
14. Feinberg AP and Vogelstein B (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92.
15. Bhusari S, Yang B, Kueck J, Huang W, and Jarrard DF (2011). Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate 71, 1621-1630.
16. Ouyang B, Leung YK, Wang V, Chung E, Levin L, Bracken B, Cheng L, and Ho SM (2011). α-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues. Urology 77, 249. e1-249. e7.
17. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, and Schubeler D (2005). Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37, 853-862.
18. Roche. NimbleGen (2010). Arrays User's Guide DNA Methylation Arrays Version 7.2.
19. Tost J, El abdalaoui H, and Gut IG (2006). Serial pyrosequencing for quantitative DNA methylation. Biotechniques 40, 721-722, 724, 726.
20. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, Li J, Thiagarajan M, White JA, and Quackenbush J (2006). TM4 microarray software suite. Methods Enzymol 411, 134-193.
21. Ruike Y, Imanaka Y, Sato F, Shimizu K, and Tsujimoto G (2010). Genomewide analysis of aberrant methylation in human breast cancer cells using methyl-DNA immunoprecipitation combined with high-throughput sequencing. BMC Genomics 11, 137.
22. Wilson IM, Davies JJ, WeberM, Brown CJ, Alvarez CE, MacAulayC, SchübelerD, and LamWL (2006). Epigenomics:mapping themethylome. Cell Cycle 5, 155-158.
23. Ayala AG and Ro JY (2007). Prostatic intraepithelial neoplasia: recent advances. Arch Pathol Lab Med 131, 1257-1266.
24. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, and Brakenhoff RH (2003). A genetic explanation of slaughter's concept of field cancerization. Cancer Res 63, 1727-1730.
25. Garcia SB, Park HS, Novelli M, and Wright NA (1999). Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. J Pathol 187, 61-81.
26. Hu M, Yao J, Cai L, Bachman KE, van den Brule F, Velculescu V, and Polyak K (2005). Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 37, 899-905.
27. Wolff EM, Chihara Y, Pan F, Weisenberger DJ, Siegmund KD, Sugano K, Kawashima K, Laird PW, Jones PA, and Liang G (2010). Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res 70, 8169-8178.
28. Takamaru H, Yamamoto E, Suzuki H, Nojima M, Maruyama R, Yamano HO, Yoshikawa K, Kimura T, Harada T, Ashida M, et al. (2012). Aberrant methylation of RASGRF1 is associated with an epigenetic field defect and increased risk of gastric cancer. Cancer Prev Res (Phila) 5, 1203-1212.
29. Yang B, Sun H, Lin W, Hou W, Li H, Zhang L, Li F, Gu Y, Song Y, Li Q, et al. (2011). Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry. Urol Oncol, E-pub ahead of print.
30. Fu VX, Dobosy JR, Desotelle JA, Almassi N, Ewald JA, Srinivasan R, Berres M, Svaren J, Weindruch R, and Jarrard DF (2008). Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Res 68, 6797-6802.
31. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom Witzel S, Okano H, Ko MS, Ohlsson R, Longo DL, and Feinberg AP (2005). Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307, 1976-1978.
32. Mathers JC, Strathdee G, and Relton CL (2010). Induction of epigenetic alterations by dietary and other environmental factors. Adv Genet 71, 3-39.
33. Waterland RA and Jirtle RL (2003). Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 23, 5293-5300.
34. Saxonov S, Berg P, and Brutlag DL (2006). A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 103, 1412-1417.
35. Park JY (2010). Promoter hypermethylation in prostate cancer. Cancer Control 17, 245-255.
36. Cooper CS and Foster CS (2009). Concepts of epigenetics in prostate cancer development. Br J Cancer 100, 240-245.
37. Ball MP, Li JB, Gao Y, Lee JH, LeProust EM, Park IH, Xie B, Daley GQ, and Church GM (2009). Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 27, 361-368.
38. Clark SJ (2007). Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis. Hum Mol Genet 16, R88-R95.
39. Truong M, Yang B, Livermore A, Wagner J, Weeratunga P, Huang W, Dhir R, Nelson J, Lin DW, and Jarrard DF (2012). Employing the epigenetic field defect to detect prostate cancer in biopsy-negative patients. J Urol, E-pub ahead of print.